G. Mason

发表

Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size.

L. Liberman, E. Morris, D. Dershaw, 2006, AJR. American journal of roentgenology.

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

A. Panigrahy, I. Pollack, L. Butterfield, 2016, Neuro-oncology.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

A. Panigrahy, I. Pollack, L. Butterfield, 2016, Journal of Neuro-Oncology.

Quality of Life Following Amputation or Limb Preservation in Patients with Lower Extremity Bone Sarcoma

Mimi Y. Kim, J. Healey, G. Mason, 2013, Front. Oncol..

Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children with Germline DNA Replication Repair Deficiency

Trevor J Pugh, K. Cole, T. Pugh, 2021 .

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report.

G. Mason, M. Tamber, M. Mcdowell, 2017, Journal of neurosurgery. Pediatrics.

Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition.

Trevor J Pugh, T. Pugh, C. Hawkins, 2021, Cancer discovery.

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

E. Small, D. Rathkopf, D. Olmos, 2022, Journal of Clinical Oncology.

A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation

P. Burger, F. Rodriguez, R. Packer, 2015, Acta Neuropathologica.

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

F. Saad, H. Scher, D. George, 2019, Annals of Oncology.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells.

G. Getz, K. Cole, T. Kunkel, 2020, Cancer discovery.

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

D. Merico, Z. Cohen, C. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Analysis of Hypermutation in Human Cancer

K. Cole, P. Raman, C. Hawkins, 2017, Cell.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

H. Scher, D. Danila, O. Ståhl, 2022, The Lancet. Oncology.

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Trevor J Pugh, K. Cole, T. Pugh, 2022, Nature Medicine.

Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns

David T. W. Jones, K. Cole, W. Mason, 2020, Acta Neuropathologica.

Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report

R. Packer, L. Vezina, Cheng-Ying Ho, 2016, Oncotarget.

Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-β as Involved in the Pathogenesis of Osteosarcoma

N. Neophytou, J. Healey, H. Dorfman, 2016, Clinical orthopaedics and related research.

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Trevor J Pugh, K. Cole, T. Pugh, 2022, Nature medicine.

Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

W. Foulkes, C. Hawkins, G. Nicholas, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.

K. Cole, W. Foulkes, W. Mason, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

A. Panigrahy, A. Furtado, S. Blüml, 2017, Neuroimaging clinics of North America.

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

E. Small, D. Rathkopf, D. Olmos, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study

B. Ertl-Wagner, W. Libionka, D. Stearns, 2022, Neuro-Oncology.

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

F. Saad, H. Scher, D. George, 2020 .

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

E. Small, D. Rathkopf, D. Olmos, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

E. Small, D. Rathkopf, D. Olmos, 2022, Journal of Clinical Oncology.

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

E. Small, D. Rathkopf, D. Olmos, 2023, Journal of Clinical Oncology.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2021, Prostate Cancer and Prostatic Diseases.

Y. Liu, K. Bevans, D. Danila, 2023, Journal of managed care & specialty pharmacy.